Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
about
Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccineToll-like receptors in antiviral innate immunityInterferons and viruses: an evolutionary arms race of molecular interactionsCationic lipid-formulated DNA vaccine against hepatitis B virus: immunogenicity of MIDGE-Th1 vectors encoding small and large surface antigen in comparison to a licensed protein vaccineImmunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection.Hepatitis B virus large surface protein: function and fame.Immunomodulatory spherical nucleic acids.Development of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients.A mouse model for HBV immunotolerance and immunotherapy.Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections.Recent progress concerning CpG DNA and its use as a vaccine adjuvant.Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.Old and new adjuvants for hepatitis B vaccines.Tumour virus vaccines: hepatitis B virus and human papillomavirus.Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B.Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer-Assisted Compaction.Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B.
P2860
Q26777516-3AEAAF11-2614-4BA0-B96A-3FDBC48F3831Q27011462-2A8AA482-6921-4278-B447-6A36433A0DD3Q28083788-7B49584B-5297-48FF-A758-7F722086BCFDQ28656316-AEAFFAE7-501E-4331-B9BA-903BB9FC93C2Q34621859-CD96AD8F-C52C-4E32-93AA-74CF2DD5A57DQ35008279-F88B4B0E-C62A-4D16-AD09-06694B5F7B03Q35055364-317DBA1C-6BE2-46E9-9342-13D2C0D59DF4Q35279697-25B32443-28CC-4603-8548-8E47182C668CQ35629312-EFADA717-DD76-48FB-A6D2-B5B1EA9972CEQ37727712-A8993E32-B42D-4473-95FA-45E8B8BDDEB3Q38011249-02C6C96E-0C26-40AC-84E8-08037D3EC611Q38168903-A376E983-0CDD-4C90-9400-114435940E8BQ38270733-7580BB1D-AA8C-4346-84EC-2D9EDF7D4274Q38293586-09467436-140E-473E-AC1C-497752A11C9FQ40046649-F9BC48D1-82FC-4AEB-A912-763765D6EA84Q47553095-FE917802-7406-4580-BBA1-22FC566337D9Q47937462-07DDC9C4-B5A7-4D1E-B8AA-0BDB3416A303Q49997050-F202A33F-255E-4D34-BDE4-8287DBC856FC
P2860
Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@en
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@nl
type
label
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@en
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@nl
prefLabel
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@en
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@nl
P2860
P356
P1476
Hepatitis B surface antigen-10 ...... HEPLISAV™ safety and efficacy.
@en
P2093
Curtis Cooper
David Mackie
P2860
P304
P356
10.1586/ERV.10.162
P577
2011-04-01T00:00:00Z